These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 9137960)
1. Adverse and beneficial immunological effects of purine nucleoside analogues. Dighiero G Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S75-81. PubMed ID: 9137960 [TBL] [Abstract][Full Text] [Related]
2. New purine analogues for the treatment of chronic B-cell malignancies. Gribbin TE Henry Ford Hosp Med J; 1991; 39(2):98-102. PubMed ID: 1679757 [TBL] [Abstract][Full Text] [Related]
5. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Pettitt AR; Sherrington PD; Cawley JC Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628 [TBL] [Abstract][Full Text] [Related]
7. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy. Fabianowska-Majewska K; Wyczechowska D Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193 [TBL] [Abstract][Full Text] [Related]
8. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. Cheson BD; Vena DA; Barrett J; Freidlin B J Clin Oncol; 1999 Aug; 17(8):2454-60. PubMed ID: 10561309 [TBL] [Abstract][Full Text] [Related]
9. Pentostatin in chronic lymphocytic leukemia. Sauter C; Lamanna N; Weiss MA Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115 [TBL] [Abstract][Full Text] [Related]
10. New drugs in the treatment of chronic lymphocytic leukemia. Keating MJ; O'Brien S; Robertson L; Plunkett W; Kantarjian H; Koller C Leukemia; 1992 Nov; 6 Suppl 4():140-1. PubMed ID: 1359203 [No Abstract] [Full Text] [Related]
11. Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia. Med Lett Drugs Ther; 1992 Sep; 34(879):89-90. PubMed ID: 1355592 [No Abstract] [Full Text] [Related]
12. Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia. Kay NE Semin Hematol; 2006 Apr; 43(2 Suppl 2):S50-4. PubMed ID: 16549115 [TBL] [Abstract][Full Text] [Related]
13. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases. Spiers AS Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224 [TBL] [Abstract][Full Text] [Related]
14. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Van den Neste E; Cardoen S; Offner F; Bontemps F Int J Oncol; 2005 Oct; 27(4):1113-24. PubMed ID: 16142330 [TBL] [Abstract][Full Text] [Related]
15. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies. Dearden CE; Matutes E; Catovsky D Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047 [TBL] [Abstract][Full Text] [Related]
16. New prospects in the treatment of indolent lymphomas with purine analogues. Cheson BD Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S27-36. PubMed ID: 9672772 [TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies. Saven A Semin Hematol; 1993 Oct; 30(4 Suppl 6):31-3. PubMed ID: 7908757 [No Abstract] [Full Text] [Related]
18. [Nucleoside analogues--new drugs for the treatment of lymphatic cancers]. Itälä M; Remes K Duodecim; 2001; 117(2):162-9. PubMed ID: 12092367 [No Abstract] [Full Text] [Related]